CYCLOSERINE Final text for addition to The International Pharmacopoeia. (November 2008) CYCLOSERINUM CYCLOSERINE

Similar documents
LUMEFANTRINUM LUMEFANTRINE

EFAVIRENZ Final text for addition to The International Pharmacopoeia

NEVIRAPINE ORAL SUSPENSION Final text for addition to The International Pharmacopoeia (February 2009)

ARTEMETHER AND LUMEFANTRINE TABLETS: Final text for addition to The International Pharmacopoeia (July 2008)

ARTEMETHER AND LUMEFANTRINE ORAL SUSPENSION:Final text for addition to The International Pharmacopoeia (November 2008)

DOXYCYCLINE HYCLATE Final text to replace published monograph in The International Pharmacopoeia (November 2007)

MEDROXYPROGESTERONE INJECTION

FLUDEOXYGLUCOSE ( 18 F) INJECTION: Final text for addition to The International Pharmacopoeia (January 2009)

Ondansetron Hydrochloride Tablets

BRIEFING. (EXC: K. Moore.) RTS C Propylparaben C 10 H 12 O Benzoic acid, 4 hydroxy, propyl ester; Propyl p hydroxybenzoate [ ].

Egualen Sodium Granules

BRIEFING. Pharmacopeial Discussion Group Sign Off Document Attributes EP JP USP Definition Loss on drying Readily carbonizable substances

USP 36 Official Monographs / Metformin carding the first 3 ml of filtrate. Transfer 25 ml of the Analysis

Revision Bulletin 27 Jan Feb 2017 Non-Botanical Dietary Supplements Compliance

The Nitrofurantoin Capsules Revision Bulletin supersedes the currently official monograph.

Amendment to the Enforcement Ordinance of the Food Sanitation Law and the Standards and Specifications for Foods and Food Additives.

Revision Bulletin 29 Dec Jan 2018 Non-Botanical Dietary Supplements Compliance

This method describes the identification of the following prohibited colorants in cosmetic products:

CHAPTER - 3 ANALYTICAL PROFILE. 3.1 Estimation of Drug in Pharmaceutical Formulation Estimation of Drugs

ADVANTAME. Not less than 97.0% and not more than 102.0% on the anhydrous basis. Sweetener, flavour enhancer

7. Stability indicating analytical method development and validation of Ramipril and Amlodipine in capsule dosage form by HPLC.

Dissolution Test 5 was validated using a Zodiac C18 brand of L1 column. The typical retention time for atorvastatin is about min.

Should you have any questions, please contact Mary P. Koleck, Ph.D., Scientific Liaison ( or

GUACO FOR HOMOEOPATHIC PREPARATIONS GUACO FOR HOMOEOPATHIC PREPARATIONS

Dehydrated Alcohol. » Dehydrated Alcohol contains not less than 99.2 percent, Pharmacopeial Forum Vol. 30(5) [Sept. Oct. 2004] HARMONIZATION 1847

Additionally, minor editorial changes have been made to update the monograph to current USP style.

ASPARTAME. Not less than 98% and not more than 102% on the dried basis. White, odourless, crystalline powder, having a strong sweet taste

12 Nicarbazin Nicarbazin (4,4 -dinitro carbanilid (DNC) and 2-hydroxy-4,6-dimethyl pyrimidine (HDP))

Chapter 5: Identification, Assay and Related Substances

INDIGOTINE. Disodium 3,3'-dioxo-[delta 2,2' -biindoline]-5,5'-disulfonate (principal component) (principal component)

ADVANTAME (TENTATIVE)

Chapter 4: Verification of compendial methods

The Isosorbide Mononitrate Extended-Release Tablets Revision Bulletin supersedes the currently official monograph.

contents of the currently official monograph. Please refer to the current edition of the USP NF for official text.

IDENTIFICATION OF STEROIDS IN COSMETIC PRODUCTS BY TLC AND HPLC 1 02/12/2005 ACM 007 A. THIN LAYER CHROMATOGRAPHY (TLC)

IDENTIFICATION AND DETERMINATION OF HYDROQUINONE IN COSMETIC PRODUCTS 2 14/11/17 ACM 003 BY TLC AND HPLC

DETERMINATION OF DRUG RELEASE DURING DISSOLUTION OF NICORANDIL IN TABLET DOSAGE FORM BY USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY

--> Buy True-PDF --> Auto-delivered in 0~10 minutes. GB Translated English of Chinese Standard: GB5009.

ANALYTICAL METHOD PROCEDURES

--> Buy True-PDF --> Auto-delivered in 0~10 minutes. GB Translated English of Chinese Standard: GB5009.

SODIUM PERTECHNETATE ( 99m Tc) INJECTION (FISSION): Revised Final text for addition to The International Pharmacopoeia (January September 2009)

contents of the currently official monograph. Please refer to the current edition of the USP NF for official text.

TEMPLATE FOR AN EXAMPLE STANDARD TEST METHOD

USP 35 Official Monographs / Oxaliplatin 4143 DEFINITION

Lonicera japonica Flower Powder. Proposed For Development Version 0.1. Published on Herbal Medicines Compendium (

METHOD DEVELOPMENT AND VALIDATION OF RALTEGRAVIR POTASSIUM AND RILPIVIRINE HCL BY HPLC AND HPTLC METHODS

STABILITY INDICATING METHOD OF RELATED IMPURITIES IN VENLAFAXINE HYDROCHLORIDE SUSTAINED RELEASE TABLETS

H 3 CO H 3 CO S CH 3

TERTIARY BUTYLHYDROQUINONE

Revision Bulletin Official April 1, 2014 Alprazolam 1

CHAPTER V ANALYTICAL METHODS ESTIMATION OF DICLOFENAC. Diclofenac (gift sample from M/s Micro Labs Ltd., Pondicherry)

H - Helium R... Hypoxanthine R

Development and Validation of a HPLC Method for Chlorphenamine Maleate Related Substances in Multicomponents Syrups and Tablets

Lonicera japonica Flower Dry Extract. Proposed For Development Version 0.1. Published on Herbal Medicines Compendium (

School of Chemistry UNIVERSITY OF KWAZULU-NATAL, WESTVILLE CAMPUS JUNE 2009 EXAMINATION CHEM340: INSTRUMENTAL ANALYSIS.

Validated RP-HPLC Method for Estimation of Cefprozil in Tablet Dosage Form

CIPAC. CIPAC Free relevant impurities methods:

Abstract. Introduction

POLYVINYL ALCOHOL. SYNONYMS Vinyl alcohol polymer, PVOH, INS No DEFINITION DESCRIPTION FUNCTIONAL USES CHARACTERISTICS

Mashhour Ghanem 1 and Saleh Abu-Lafi 2 * ABSTRACT ARTICLE INFO

Introduction to Pharmaceutical Chemical Analysis

A Simple, Novel Validated Stability Indicating RP-HPLC method for estimation of Duloxetine HCl in Capsule Pharmaceutical Formulation

Certificate of Analysis

PHENYLEPHRINE HYDROCHLORIDE CERTIFIED REFERENCE MATERIAL

Chapter content. Reference

SPECIFIC MONOGRAPH TECHNETIUM ( 99M TC) SUCCIMER INJECTION

Identification and Determination Methods of Aspartame

Int. J. Pharm. Sci. Rev. Res., 30(2), January February 2015; Article No. 09, Pages: 63-68

Impact factor: 3.958/ICV: 4.10 ISSN:

Stability indicating RP-HPLC method for determination of azilsartan medoxomil in bulk and its dosage form

A RP-HPLC METHOD DEVELOPMENT AND VALIDATION OF PARA- PHENYLENEDIAMINE IN PURE FORM AND IN MARKETED PRODUCTS

Teacher Resource and Assessment Book Exercises Unit 3 answers

Research of Quality Standards for Stachydrine Hydrochloride in Chinese Medicine TJF Granule

PDG.pdf G-20 CHROMATOGRAPHY 3 4 INTRODUCTION

TECHNICAL BRODIFACOUM

Thin Layer Chromatography

ASPIRIN (ACETYLSALICYLIC ACID) CERTIFIED REFERENCE MATERIAL

GENERAL PHARMACOPOEIA MONOGRAPH

Modernizing the USP Monograph for Acetaminophen

Asian Journal of Research in Chemistry and Pharmaceutical Sciences Journal home page:

DEVELOPMENT AND VALIDATION OF NEW RP-HPLC METHOD FOR THE DETERMINATION OF AFLOQUALONE IN HUMAN PLASMA AND FORMULATION

SPECIFICATION & TEST PROCEDURE SODIUM SALICYLATE Technical. Molecular weight : Reference : In-house

Abstract: An minimalist overview of chromatography for the person who would conduct chromatographic experiments, but not design experiments.

Stability-indicating HPLC determination of tolterodine tartrate in pharmaceutical dosage form

METHOTREXATE mg/m 3 (arbitrary). There is no OSHA PEL or AGGIH TLV for

Dissolution Test 2 was validated using an Inertsil ODS-3V brand of L1 column. The typical retention time for donepezil is about 5.5 min.

Chromatography. Gas Chromatography

Reverse Phase High Performance Liquid Chromatography method for determination of Lercanidipine hydrochloride in bulk and tablet dosage form

LC Determination of Deferasirox in Pharmaceutical Formulation

A. GENERAL NOTICES. Ninth Edition, which may be abbreviated as JSFA-IX.

High Pressure/Performance Liquid Chromatography (HPLC)

Appendix II- Bioanalytical Method Development and Validation

DEVELOPMENT AND VALIDATION OF NEW ANALYTICAL METHOD FOR BIOACTIVE COMPOUNDS

ANALYTICAL METHOD DETERMINATION OF VOLATILE ALDEHYDES IN AMBIENT AIR Page 1 of 11 Air sampling and analysis

Simultaneous estimation of meclizine and nicotinic acid by using RP-HPLC

Analytical Method Development and Validation of Lafutidine in Tablet dosage form by RP-HPLC

GB/T Translated English of Chinese Standard: GB/T

Shodex TM ODP2 HP series columns

High-Performance Liquid Chromatographic Method for the Analysis of Fluconazole in Pharmaceutical Preparations

Saudi Journal of Medical and Pharmaceutical Sciences

Transcription:

December 2008 CYCLOSERINE Final text for addition to The International Pharmacopoeia (November 2008) This monograph was adopted at the Forty-third WHO Expert Committee on Specifications for Pharmaceutical Preparations in October 2008 for addition to the 4 th Edition of the International Pharmacopoeia CYCLOSERINUM CYCLOSERINE O HN O NH 2 H C 3 H 6 N 2 O 2 Relative molecular mass. 102.1 Chemical name. (R)-(+)-4-Amino-3-isoxazolidinone; (R)-4-aminoisoxazolidin-3-one; CAS Reg. No. 68-41-7. Description. A white or pale yellow, crystalline powder. Solubility. Freely soluble in water; slightly soluble in methanol R and propylene glycol R; very slightly soluble in ethanol ( 750 g/l) TS; practically insoluble in dichloromethane R. Category. Antibacterial drug; antituberculosis drug. Storage. Cycloserine should be kept in a tightly closed container.

page 2 Additional information. Cycloserine is slightly hygroscopic and degrades upon exposure to a humid atmosphere ; decomposition being faster at higher temperatures. Requirements Definition. Cycloserine is an analogue of the amino acid D-alanine with broad-spectrum antibiotic and glycinergic activities produced by Streptomyces garyphalus and Streptomyces orchidaceus or obtained by synthesis. Cycloserine contains not less than 98.5% and not more than 101.5% of cycloserine (C 3 H 6 N 2 O 2 ), calculated with reference to the dried substance. Identity tests Either tests A and C, or tests B and C, or test D alone may be applied. A. Carry out test A.1. or, where UV detection is not available, test A.2. A.1. Carry out the test as described under 1.14.1 Thin-layer chromatography, using silica gel R6 as the coating substance and a mixture of 4 volumes of 1-butanol R, 1 volume of glacial acetic acid R and 2 volumes of water R as the mobile phase. Apply separately to the plate 10 µl of each of the following two solutions. For solution (A), dissolve 20 mg of the test substance in 0.5 ml of water R, add 4.5 ml of methanol R and shake. For solution (B), use 20 mg of cycloserine RS prepared in the same manner. After removing the plate from the chromatographic chamber, allow it to dry exhaustively in a current of air. Examine the chromatogram in ultraviolet light (254 nm). The principal spot obtained with solution A corresponds in position, appearance, and intensity with that obtained with solution B. A.2. Carry out the test as described under 1.14.1 Thin-layer chromatography, using the conditions described above under test A.1., but using silica gel R5 as the coating substance. After removing the plate from the chromatographic chamber, allow it to dry in a current of air and place the plate in a chamber with iodine vapours. Examine the chromatogram in daylight. The principal spot obtained with solution A corresponds in position, appearance, and intensity with that obtained with solution B.

page 3 B. Dissolve about 1 mg in 10 ml of sodium hydroxide (0.1 mol/l) VS. To 1 ml of the resulting solution add 3 ml of acetic acid (~60 g/l) TS and 1 ml of a recently prepared mixture of equal volumes of a 40 mg/ml solution of sodium nitroprusside R and sodium hydroxide ( 200 g/l) TS; a blue colour gradually develops. C. The absorption spectrum (1.6) of a freshly prepared 25 µg/ml solution in hydrochloric acid (0.1mol/l) VS, when observed between 215 nm and 360 nm, exhibits a maximum at about 219 nm; the specific absorbance (A 1cm 1% ) is between 327 and 361. D. Carry out the examination as described under 1.7 Spectrophotometry in the infrared region. The infrared absorption spectrum is concordant with the spectrum obtained from cycloserine RS or with the reference spectrum of cycloserine. Specific optical rotation (1.4). Use a 50 mg/ml solution in sodium hydroxide (~80 g/l) TS and calculate with reference to the dried substance; [α] D 20 C = +108 to +114. Heavy metals. Use 2.0 g for the preparation of the test solution as described under 2.2.3 Limit test for heavy metals, Procedure 3; determine the heavy metals content according to Method A; not more than 10 µg/g. Sulfated ash (2.3). Not more than 5.0 mg/g. Loss on drying. Dry at 60 C under reduced pressure (not exceeding 0.6 kpa or about 5 mm of mercury) for 3 hours; it loses not more than 10 mg/g. ph value (1.13). ph of a 100 mg/ml solution in carbon-dioxide-free water R, 5.5 to 6.5. Related substances Prepare fresh solutions and perform the tests without delay. Carry out the test as described under 1.14.4 High-performance liquid chromatography, using a stainless steel column (25 cm x 4.6 mm) packed with base deactivated particles of silica gel the surface of which has been modified with chemically bonded octadecylsilyl groups (5 µm) 1. The mobile phases for gradient elution consist of a mixture of mobile phase A and mobile phase B, using the following conditions: Mobile phase A: 4 volumes of acetonitrile R, 70 volumes of 0.02 mol/l sodium octanesulfonate R solution, 10 volumes of phosphate buffer ph 2.8 and 16 volumes of water R. 1 Hypersil BDS

page 4 Mobile phase B: 17 volumes of acetonitrile R, 70 volumes of 0.02 mol/l sodium octanesulfonate R solution, 10 volumes of phosphate buffer ph 2.8 and 3 volumes of water R. Prepare the sodium octanesulfonate solution by dissolving 4.7 g of sodium octanesulfonate R in 1000 ml of water R. Prepare the phosphate buffer ph 2.8 by dissolving 27.2 g of potassium dihydrogen phosphate R in 800 ml of water R, adjust the ph to 2.8 by adding phosphoric acid (~20 g/l) TS and dilute to 1000 ml with water R. Time Mobile phase A Mobile phase B Comments (min) (% v/v) (% v/v) 0 16 100 0 Isocratic 16 18 100 to 0 0 to 100 Linear gradient 18 22 0 100 Isocratic 22 24 24 30 0 to 100 100 100 to 0 0 Return to initial composition Re-equilibration Prepare the following solutions in mobile phase A. For solution (1) use 0.5 mg of the test substance per ml. For solution (2) dilute a suitable volume of solution (1) to obtain a concentration equivalent to 0.5 µg of cycloserine per ml. For solution (3) dilute a suitable volume of solution (1) to obtain a concentration equivalent to 25 µg of cycloserine per ml. Heat carefully in a boiling water-bath for 30 minutes. Operate with a flow rate of 1.0 ml per minute. As a detector use an ultraviolet spectrophotometer set at a wavelength of 219 nm. Maintain the column temperature at 45 C. Inject 50 µl of solution (3). The test is not valid unless the resolution between the principal peak and the large degradation peak with a retention time of about 3 minutes is not less than 35. If necessary adjust the amount of acetonitrile in mobile phase A. Inject alternatively 50 µl each of solutions (1) and (2). In the chromatogram obtained with solution (1), the area of any peak, other than the principal peak, is not greater than twice the area of the principal peak in the chromatogram obtained with solution (2) (0.2%). The sum of the areas of all peaks, other than the principal peak, is not greater than five times the area of the principal peak in the chromatogram obtained with solution (2) (0.5%). Disregard any peak with an area less than 0.5 times the area of the principal peak in the chromatogram obtained with solution (2) (0.05%).

page 5 Assay Dissolve about 0.1 g, accurately weighed, in 5 ml of water R. Add 75 ml of 2-propanol R and titrate with carbonate-free sodium hydroxide (0.1 mol/l) VS using thymolphthalein/ethanol TS as indicator. Perform a blank determination and make any necessary correction. Each ml of sodium hydroxide (0.1 mol/l) VS is equivalent to 10.21 mg of C 3 H 6 N 2 O 2. Impurities A. cycloserine dimer B. (2R)-2-amino-3hydroxypropanoïque (D-serine) C. condensation product with unknown structure [Note from the Secretariat: systematic chemical names of the impurities covered by this monograph to be added + mention "(b)" in structure for impurity A to be deleted] ***